1. Home
  2. COHN vs RLMD Comparison

COHN vs RLMD Comparison

Compare COHN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COHN
  • RLMD
  • Stock Information
  • Founded
  • COHN 1999
  • RLMD 2004
  • Country
  • COHN United States
  • RLMD United States
  • Employees
  • COHN N/A
  • RLMD N/A
  • Industry
  • COHN Investment Bankers/Brokers/Service
  • RLMD Biotechnology: Pharmaceutical Preparations
  • Sector
  • COHN Finance
  • RLMD Health Care
  • Exchange
  • COHN Nasdaq
  • RLMD Nasdaq
  • Market Cap
  • COHN 21.6M
  • RLMD 20.3M
  • IPO Year
  • COHN N/A
  • RLMD N/A
  • Fundamental
  • Price
  • COHN $11.83
  • RLMD $0.65
  • Analyst Decision
  • COHN
  • RLMD Buy
  • Analyst Count
  • COHN 0
  • RLMD 3
  • Target Price
  • COHN N/A
  • RLMD $5.00
  • AVG Volume (30 Days)
  • COHN 8.9K
  • RLMD 231.6K
  • Earning Date
  • COHN 08-04-2025
  • RLMD 08-06-2025
  • Dividend Yield
  • COHN 8.45%
  • RLMD N/A
  • EPS Growth
  • COHN N/A
  • RLMD N/A
  • EPS
  • COHN N/A
  • RLMD N/A
  • Revenue
  • COHN $84,171,000.00
  • RLMD N/A
  • Revenue This Year
  • COHN N/A
  • RLMD N/A
  • Revenue Next Year
  • COHN N/A
  • RLMD N/A
  • P/E Ratio
  • COHN N/A
  • RLMD N/A
  • Revenue Growth
  • COHN N/A
  • RLMD N/A
  • 52 Week Low
  • COHN $6.10
  • RLMD $0.24
  • 52 Week High
  • COHN $13.25
  • RLMD $4.24
  • Technical
  • Relative Strength Index (RSI)
  • COHN 75.00
  • RLMD 51.63
  • Support Level
  • COHN $11.00
  • RLMD $0.60
  • Resistance Level
  • COHN $13.25
  • RLMD $0.74
  • Average True Range (ATR)
  • COHN 0.45
  • RLMD 0.06
  • MACD
  • COHN 0.12
  • RLMD 0.01
  • Stochastic Oscillator
  • COHN 54.19
  • RLMD 47.88

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Share on Social Networks: